-
Mashup Score: 0Gilead (GILD): Veklury Revenues Set To Impress - 3 year(s) ago
Gilead is set to blow past revenue guidance and analyst estimates once again through increasing Veklury sales. Read to know more…
Source: SeekingAlphaCategories: Infectious Disease, Latest HeadlinesTweet
-
Mashup Score: 2Eli Lilly's mirikizumab meets primary endpoint in late-stage ulcerative colitis trial - 3 year(s) ago
Mirikizumab, a monoclonal antibody under investigation from Eli Lilly for ulcerative colitis, met its primary endpoint, clinical remission.
Source: SeekingAlphaCategories: Gastroenterology, Latest HeadlinesTweet-
RT @vipuljairath: Eli Lilly's mirikizumab meets primary endpoint in late-stage ulcerative colitis trial https://t.co/TwJ0Zom1gd https://t.c…
-
-
Mashup Score: 0GSK's Nucala OK'd in Europe for three additional eosinophil-driven diseases (NYSE:GSK) - 3 year(s) ago
GlaxoSmithKline (GSK) announces that the European Commission has approved Nucala (mepolizumab), a monoclonal antibody that targets interleukin-5, for use in three…
Source: SeekingAlphaCategories: Healthcare Professionals, Latest HeadlinesTweet-
GSK's Nucala OK'd in Europe for three additional eosinophil-driven diseases (NYSE:GSK) | Seeking Alpha https://t.co/6m46yQaeXz
-
-
Mashup Score: 0Clene shares slide 30% after mid-stage CNM-Au8 sclerosis trial fails to meet main goal - 3 year(s) ago
Clene (CLNN) announces that the company’s mid-stage trial of CNM-Au8 failed to meet the primary endpoint as a disease modifying treatment for people with early amyotrophic lateral…
Source: SeekingAlphaCategories: Latest Headlines, Rare DiseaseTweet-
$CLNN - Clene shares slide 30% after mid-stage CNM-Au8 sclerosis trial fails to meet main goal https://t.co/MWxFH3PjnE
-
-
Mashup Score: 0Intuitive presents preliminary post market data for Ion Endoluminal system for lung biopsy - 3 year(s) ago
Intuitive <
> reported data from a post-market study called PRECIsE, for its Ion endoluminal system.The company said use of the Ion system for pulmonary nodule biopsy resulted in… Source: SeekingAlphaCategories: Healthcare Professionals, Latest HeadlinesTweet-
.@IntuitiveSurg $ISRG presents preliminary post market data for Ion Endoluminal system for #lungbiopsy | #roboticsurgery https://t.co/P4dN1AohOE
-
-
Mashup Score: 36
Analysts’ consensus 12-month target is for an 18% plus upside. The company is experiencing rapid organic growth.
Source: SeekingAlphaCategories: Hem/Oncs, Latest HeadlinesTweet-
An addendum for those DM’ing me to say this is untrue, the math doesn’t work out, prior auths are *only* to prevent insurance fraud, etc. Some real numbers, from Anthem in 2019. 16% of their revenue came from investment income… $1 billion total. https://t.co/CIZr6idzx6 https://t.co/4K3rFWY1oQ
-
-
Mashup Score: 8
Drugmaker AbbVie (ABBV) has been given approval by Health Canada for its atopic dermatitis ((AD)) drug, RINVOQ (upadacitinib). RINVOQ is a once-daily oral selective JAK inhibitor
Source: SeekingAlphaCategories: Allergy-Immunology, Latest HeadlinesTweet-
$ABBV - AbbVie's atopic dermatitis drug RINVOQ gets Health Canada approval https://t.co/QVvYQJIvi2
-
-
Mashup Score: 0Merck gains after molnupiravir reduce risk of hospitalization/death due to COVID-19 by 50% - 3 year(s) ago
Merck (MRK) and Ridgeback Biotherapeutics announce results from their oral antiviral medicine molnupiravir (MK-4482, EIDD-2801) from Phase 3 MOVe-OUT trial in patients…
Source: SeekingAlphaCategories: Healthcare Professionals, Latest HeadlinesTweet-
Merck gains after molnupiravir reduces risk of hospitalization/death due to COVID-19 by 50% https://t.co/Ltec22e61h
-
-
Mashup Score: 0Biohaven shares drop 6% after verdiperstat multiple system atrophy trial data (NYSE:BHVN) - 3 year(s) ago
Biohaven Pharmaceutical Holding (BHVN) shares slide more than 6% premarket after the company’s verdiperstat treatment failed to make a statistically significant improvement in patients…
Source: SeekingAlphaCategories: Latest Headlines, Rare DiseaseTweet-
$BHVN - Biohaven shares drop 6% after verdiperstat multiple system atrophy trial data https://t.co/SUErGZwPPY
-
-
Mashup Score: 3Inflation Still Appears To Be Peaking, But For How Long? - 3 year(s) ago
Recent updates continue to suggest that the recent surge in US inflation is cresting. The mystery is how long the peaking process will last.
Source: SeekingAlphaCategories: Healthcare Professionals, Latest HeadlinesTweet-
#Inflation Still Appears To Be Peaking, But For How Long? // #economy https://t.co/sYA5n5s4mW
-
$GILD - @GileadSciences Veklury Revenues Set To Impress https://t.co/rc2QI8vfUu Sales of RDV in Q3 of 2021 were $1,923 million. COVID-19 related hospitalizations in the Q4 were at similar levels as those seen in the Q3, meaning Q4 sales will likely also come in around $2 billion.